{"success":true,"data":{"pressRelease":{"id":"126364","rtpr_id":"nGNE4BxJyP","ticker":"LKFT","exchange":"Euronext Amsterdam","all_tickers":["LKFT"],"title":"REG-Lakefront Receives Transparency Notification from Bank of America","author":"Globe Newswire","published_at":"2026-08-24T20:01:00.067Z","article_body":"Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information –\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency\nnotification from Bank of America.\n\nPursuant to Belgian transparency legislation(1), Lakefront received a\ntransparency notification from Bank of America Corporation on August 19, 2026.\nThe notification indicates that Bank of America Corporation, as controlling\nentity, crossed above the threshold of 10% of Lakefront’ voting rights on\nAugust 18, 2026, following the acquisition of Lakefront voting rights and\nequivalent financial instruments.\n\nOn August 19, 2026, Bank of America Corporation (taking into account the\nholding of its affiliates) owned 1,419,144 voting rights and 5,243,453\nequivalent financial instruments, representing together 10.11% of Lakefront’\ncurrently outstanding 65,897,071 shares.\n\nSummary of the transactions:\n\n Date on which the threshold was crossed Date of notification Direct voting rights after the transaction Equivalent financial instruments after the transaction Total (%) voting rights \n August 18, 2026 August 19, 2026 2.15% 7.96% 10.11% \n\nContent of the notification from Bank of America Corporation:\nThe notification dated August 19, 2026, contains the following information:\n•        Date of notification: August 19, 2026\n•        Date on which the threshold is crossed: August 18, 2026\n•        Threshold of voting rights crossed (in %): 10%\n•        Notification by: Bank of America Corporation\n•        Denominator: 65,897,071\n•        Reason for the notification: Acquisition or disposal of\nfinancial instruments that are treated as voting securities\n•        Notified details:\n\n A) Voting Rights Previous notification After the transaction \n # of voting rights # of voting rights % of voting rights \n Holder of voting rights Linked to securities Not linked to securities Linked to securities Not linked to securities \n Bank of America Corporation 0 0 0.00% \n Bank of America, National Association 14,348 10,701 0.02% \n Merrill Lynch International 8,234 0 0.00% \n BofA Securities, Inc. 600,314 1,407,905 2.14% \n Merrill Lynch, Pierce, Fenner & Smith Incorporated 462 462 0.00% \n U.S. Trust Company of Delaware 76 76 0.00% \n Subtotal 623,434 1,419,144 2.15% \n TOTAL 1,419,144 0 2.15% 0.00% \n\n\n\n B) Equivalent financial instruments After the transaction \n Holder of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement \n Merrill Lynch International Right to Recall 262,775 0.40% physical \n Merrill Lynch International Rights of Use 34,089 0.05% physical \n BofA Securities, Inc. Right to Use 4,757,362 7.22% physical \n Bank of America, National Association Swaps 15/10/2027 434 0.00% cash \n Bank of America, National Association Swaps 15/06/2027 13,414 0.02% cash \n Bank of America, National Association Swaps 30/06/2028 27 0.00% cash \n Bank of America, National Association Swaps 31/07/2028 3,061 0.00% cash \n Merrill Lynch International Swaps 15/01/2027 13,448 0.02% cash \n Merrill Lynch International Swaps 30/04/2027 134,182 0.20% cash \n Merrill Lynch International Swaps 30/06/2027 213 0.00% cash \n Merrill Lynch International Swaps 15/06/2027 13,414 0.02% cash \n Merrill Lynch International Swaps 09/09/2027 2,933 0.00% cash \n Merrill Lynch International Swaps 29/01/2027 3,741 0.01% cash \n Merrill Lynch International Swaps 31/03/2027 222 0.00% cash \n Merrill Lynch International Swaps 30/09/2027 44 0.00% cash \n Merrill Lynch International Swaps 26/02/2027 4,050 0.01% cash \n BofA Securities, Inc. Swaps 30/09/2027 44 0.00% cash \n TOTAL 5,243,453 7.96% \n\n\n\n TOTAL (A&B) # of voting rights % of voting rights \n 6,662,597 10.11% \n\nThe chain of control has been described at the end of the notification\n(section 11) and can be found here\n(https://www.globenewswire.com/Tracker?data=Cbh5SC1sH__bDUEmcUVlEFo0RnbZxj_ovdsTgXsh2EDvGcvkjxbWzPPtWqS9kXDbE6foJJi62k3UhdjFjyaCAxgiidPU0wp5263BRKJbGgF055I7tLPsMkVgHppYbyYtGYN4hpq1MhX8uCXBNodzHQ==).\n\nAbout Lakefront(®) Biotherapeutics\nLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology\ncompany dedicated to building a differentiated pipeline of medicines for\npatients with serious diseases in areas of high unmet need. The Company has\nestablished a clinical-stage portfolio in immunology and inflammation,\nanchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3\nT-cell engager for autoimmune diseases. Backed by deep deal-making expertise,\noperational flexibility, and a strong capital position, Lakefront identifies,\nacquires, and advances high-quality assets with clear potential to deliver\nmeaningful patient impact and long-term shareholder value. For more\ninformation, visit https://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=JF7ZFIteKsgl-8kqfhr0NhYBz_QLt9iSZ-h0mBpncfWmkMcA1bNuF1SHEz4GcZgCcIXLzMvFRD5XMeN2gqzJKsbP2sGkpkf53ubimnpBEd4k_mTTlEnYOpk9cLJg1gQmqY2-gY21VeXt47SrNY_MqiCc_1ddojfUzYiBO-e-1HuE8HVrFeBRCc9iG2jR_5mfsYD9xnJb5foPloPl946a66i5seWrgRsfW-vYr-EXRPmhRmh7f08uXexorLB_T2cXsC8CgCJBKZr86A38qwtMGA==) or X\n(https://www.globenewswire.com/Tracker?data=XGW-C0wGBzth33h4jGTMc3Syk4rSXYWJe7upw6-v7tG54pEa_FAeHwMAo2VtibGiYodsXW8Ceia5YBWp-kRP0JUizq0fiuYXrftHG08t3Sw7FFIt80suN450ffHSnozoQ_NbbnIhX_amC4ANYuYD8eq3FyYbp46kTGa5avXaIyUHv9k-datyZ0SR8VUGZejhTUaObfw0LHtMIRRQPa_jfNHqdfk8TJZlSIaX5gnjfMQ=).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nForward-looking statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\n(1) Belgian Act of 2 May 2007 on the disclosure of major shareholdings in\nissuers whose shares are admitted to trading on a regulated market and\nregarding miscellaneous provisions, as amended from time to time.\n\nAttachment\n* TN BofA_Aug 19 2026_EN (1)\n(https://ml-eu.globenewswire.com/Resource/Download/3d2c2eb6-ff17-4235-bfb0-4b0917839ff5)","article_body_html":"","raw_payload":{"data":{"id":"nGNE4BxJyP","title":"REG-Lakefront Receives Transparency Notification from Bank of America","author":"Globe Newswire","ticker":"LKFT","created":"2026-08-24T20:01:00.067Z","tickers":["LKFT"],"exchange":"Euronext Amsterdam","article_body":"Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information –\nLakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency\nnotification from Bank of America.\n\nPursuant to Belgian transparency legislation(1), Lakefront received a\ntransparency notification from Bank of America Corporation on August 19, 2026.\nThe notification indicates that Bank of America Corporation, as controlling\nentity, crossed above the threshold of 10% of Lakefront’ voting rights on\nAugust 18, 2026, following the acquisition of Lakefront voting rights and\nequivalent financial instruments.\n\nOn August 19, 2026, Bank of America Corporation (taking into account the\nholding of its affiliates) owned 1,419,144 voting rights and 5,243,453\nequivalent financial instruments, representing together 10.11% of Lakefront’\ncurrently outstanding 65,897,071 shares.\n\nSummary of the transactions:\n\n Date on which the threshold was crossed Date of notification Direct voting rights after the transaction Equivalent financial instruments after the transaction Total (%) voting rights \n August 18, 2026 August 19, 2026 2.15% 7.96% 10.11% \n\nContent of the notification from Bank of America Corporation:\nThe notification dated August 19, 2026, contains the following information:\n•        Date of notification: August 19, 2026\n•        Date on which the threshold is crossed: August 18, 2026\n•        Threshold of voting rights crossed (in %): 10%\n•        Notification by: Bank of America Corporation\n•        Denominator: 65,897,071\n•        Reason for the notification: Acquisition or disposal of\nfinancial instruments that are treated as voting securities\n•        Notified details:\n\n A) Voting Rights Previous notification After the transaction \n # of voting rights # of voting rights % of voting rights \n Holder of voting rights Linked to securities Not linked to securities Linked to securities Not linked to securities \n Bank of America Corporation 0 0 0.00% \n Bank of America, National Association 14,348 10,701 0.02% \n Merrill Lynch International 8,234 0 0.00% \n BofA Securities, Inc. 600,314 1,407,905 2.14% \n Merrill Lynch, Pierce, Fenner & Smith Incorporated 462 462 0.00% \n U.S. Trust Company of Delaware 76 76 0.00% \n Subtotal 623,434 1,419,144 2.15% \n TOTAL 1,419,144 0 2.15% 0.00% \n\n\n\n B) Equivalent financial instruments After the transaction \n Holder of equivalent financial instruments Type of financial instrument Expiration date Exercise period or date # of voting rights that may be acquired if the instrument is exercised % of voting rights Settlement \n Merrill Lynch International Right to Recall 262,775 0.40% physical \n Merrill Lynch International Rights of Use 34,089 0.05% physical \n BofA Securities, Inc. Right to Use 4,757,362 7.22% physical \n Bank of America, National Association Swaps 15/10/2027 434 0.00% cash \n Bank of America, National Association Swaps 15/06/2027 13,414 0.02% cash \n Bank of America, National Association Swaps 30/06/2028 27 0.00% cash \n Bank of America, National Association Swaps 31/07/2028 3,061 0.00% cash \n Merrill Lynch International Swaps 15/01/2027 13,448 0.02% cash \n Merrill Lynch International Swaps 30/04/2027 134,182 0.20% cash \n Merrill Lynch International Swaps 30/06/2027 213 0.00% cash \n Merrill Lynch International Swaps 15/06/2027 13,414 0.02% cash \n Merrill Lynch International Swaps 09/09/2027 2,933 0.00% cash \n Merrill Lynch International Swaps 29/01/2027 3,741 0.01% cash \n Merrill Lynch International Swaps 31/03/2027 222 0.00% cash \n Merrill Lynch International Swaps 30/09/2027 44 0.00% cash \n Merrill Lynch International Swaps 26/02/2027 4,050 0.01% cash \n BofA Securities, Inc. Swaps 30/09/2027 44 0.00% cash \n TOTAL 5,243,453 7.96% \n\n\n\n TOTAL (A&B) # of voting rights % of voting rights \n 6,662,597 10.11% \n\nThe chain of control has been described at the end of the notification\n(section 11) and can be found here\n(https://www.globenewswire.com/Tracker?data=Cbh5SC1sH__bDUEmcUVlEFo0RnbZxj_ovdsTgXsh2EDvGcvkjxbWzPPtWqS9kXDbE6foJJi62k3UhdjFjyaCAxgiidPU0wp5263BRKJbGgF055I7tLPsMkVgHppYbyYtGYN4hpq1MhX8uCXBNodzHQ==).\n\nAbout Lakefront(®) Biotherapeutics\nLakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology\ncompany dedicated to building a differentiated pipeline of medicines for\npatients with serious diseases in areas of high unmet need. The Company has\nestablished a clinical-stage portfolio in immunology and inflammation,\nanchored by gamgertamig, a potential first-in-class and best-in-class BCMAxCD3\nT-cell engager for autoimmune diseases. Backed by deep deal-making expertise,\noperational flexibility, and a strong capital position, Lakefront identifies,\nacquires, and advances high-quality assets with clear potential to deliver\nmeaningful patient impact and long-term shareholder value. For more\ninformation, visit https://www.lakefrontbio.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=JF7ZFIteKsgl-8kqfhr0NhYBz_QLt9iSZ-h0mBpncfWmkMcA1bNuF1SHEz4GcZgCcIXLzMvFRD5XMeN2gqzJKsbP2sGkpkf53ubimnpBEd4k_mTTlEnYOpk9cLJg1gQmqY2-gY21VeXt47SrNY_MqiCc_1ddojfUzYiBO-e-1HuE8HVrFeBRCc9iG2jR_5mfsYD9xnJb5foPloPl946a66i5seWrgRsfW-vYr-EXRPmhRmh7f08uXexorLB_T2cXsC8CgCJBKZr86A38qwtMGA==) or X\n(https://www.globenewswire.com/Tracker?data=XGW-C0wGBzth33h4jGTMc3Syk4rSXYWJe7upw6-v7tG54pEa_FAeHwMAo2VtibGiYodsXW8Ceia5YBWp-kRP0JUizq0fiuYXrftHG08t3Sw7FFIt80suN450ffHSnozoQ_NbbnIhX_amC4ANYuYD8eq3FyYbp46kTGa5avXaIyUHv9k-datyZ0SR8VUGZejhTUaObfw0LHtMIRRQPa_jfNHqdfk8TJZlSIaX5gnjfMQ=).\n\nFor further information, contact Lakefront Biotherapeutics:\nInvestor Relations \nSherri Spear\n+1 412 522 6418\nsherri.spear@lakefrontbio.com\n\nForward-looking statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, all of which involve\ncertain risks and uncertainties. These statements are often, but are not\nalways, made through the use of words or phrases such as “believe,”\n“anticipate,” “expect,” “intend,” “plan,” “seek,”\n“upcoming,” “future,” “estimate,” “may,” “will,”\n“could,” “would,” “potential,” “forward,” “goal,”\n“next,” “continue,” “should,” “encouraging,” “aim,”\n“progress,” “remain,” “explore,” and “further,” as well as\nsimilar expressions. These statements include, but are not limited to,\nstatements regarding Lakefront’s plans to repurchase its ordinary shares.\nLakefront cautions the reader that forward-looking statements are based on our\nmanagement’s current expectations and beliefs and are not guarantees of\nfuture performance. Forward-looking statements may involve known and unknown\nrisks, uncertainties and other factors which might cause actual events,\nfinancial condition and liquidity, performance, or achievements, or the\nindustry in which we operate, to be materially different from any historic or\nfuture results, financial conditions, performance or achievements expressed or\nimplied by such forward-looking statements. In addition, even if our results,\nperformance, financial condition and liquidity, and the development of the\nindustry in which Lakefront operates are consistent with such forward-looking\nstatements, they may not be predictive of results or developments in future\nperiods. Such risks include, but are not limited to, those risks and\nuncertainties that can be found in our filings and reports with the Securities\nand Exchange Commission (“SEC”), including in our most recent annual\nreport on Form 20-F filed with the SEC and our subsequent filings and reports\nfiled with the SEC. Given these risks and uncertainties, the reader is advised\nnot to place any undue reliance on such forward-looking statements. In\naddition, even if the result of our operations, financial condition and\nliquidity, or the industry in which we operate, are consistent with such\nforward-looking statements, they may not be predictive of results, performance\nor achievements in future periods. These forward-looking statements speak only\nas of the date of publication of this release. We expressly disclaim any\nobligation to update any such forward-looking statements in this release to\nreflect any change in our expectations or any change in events, conditions or\ncircumstances, unless specifically required by law or regulation.\n\n(1) Belgian Act of 2 May 2007 on the disclosure of major shareholdings in\nissuers whose shares are admitted to trading on a regulated market and\nregarding miscellaneous provisions, as amended from time to time.\n\nAttachment\n* TN BofA_Aug 19 2026_EN (1)\n(https://ml-eu.globenewswire.com/Resource/Download/3d2c2eb6-ff17-4235-bfb0-4b0917839ff5)"},"type":"article","timestamp":"2026-08-24T20:01:00.171983322Z","server_sent_at_ms":1787601660171},"received_at":"2026-08-24T20:01:00.301Z","source_url":null},"analysis":{"id":"115307","press_release_id":"126364","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"regulatory","narrative":"Lakefront Biotherapeutics received a transparency notification from Bank of America indicating the bank crossed the 10% threshold of voting rights on August 18, 2026.\n\nThe filing details that Bank of America and its affiliates hold 1,419,144 direct voting rights and 5,243,453 equivalent financial instruments, representing a total 10.11% interest in the company.\n\nThe disclosure was made pursuant to Belgian transparency legislation regarding major shareholdings in issuers admitted to trading on a regulated market.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Bank of America crosses 10% ownership threshold via financial instruments."},"keyFigures":{"customDimensions":{"shares_outstanding":65897071,"total_ownership_pct":"10.11%","direct_voting_rights":1419144,"voting_rights_threshold":"10%","equivalent_financial_instruments":5243453}},"quotedText":"","namedEntities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT"},{"name":"Bank of America Corporation","ticker":"BAC","relationship":"shareholder"},{"name":"Bank of America, National Association","relationship":"shareholder affiliate"},{"name":"Merrill Lynch International","relationship":"shareholder affiliate"},{"name":"BofA Securities, Inc.","relationship":"shareholder affiliate"},{"name":"Merrill Lynch, Pierce, Fenner & Smith Incorporated","relationship":"shareholder affiliate"},{"name":"U.S. Trust Company of Delaware","relationship":"shareholder affiliate"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Standard regulatory filing disclosing that Bank of America crossed a 10% voting rights threshold. While the size of the position is notable, the filing is a procedural transparency notification under Belgian law with no direct operational impact on the company stated."},"tickerRelevance":{"others":[{"ticker":"BAC","relevance":"shareholder"}],"primary":"LKFT"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-mid-cap","eventGravity":"regulatory_disclosure","sectorWeight":"biotech"}},"event_type":"regulatory","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Lakefront Biotherapeutics received a transparency notification from Bank of America indicating the bank crossed the 10% threshold of voting rights on August 18, 2026.\n\nThe filing details that Bank of America and its affiliates hold 1,419,144 direct voting rights and 5,243,453 equivalent financial instruments, representing a total 10.11% interest in the company.\n\nThe disclosure was made pursuant to Belgian transparency legislation regarding major shareholdings in issuers admitted to trading on a regulated market.","key_figures":{"customDimensions":{"shares_outstanding":65897071,"total_ownership_pct":"10.11%","direct_voting_rights":1419144,"voting_rights_threshold":"10%","equivalent_financial_instruments":5243453}},"named_entities":{"people":[{"name":"Sherri Spear","role":"Investor Relations"}],"products":["gamgertamig"],"companies":[{"name":"Lakefront Biotherapeutics NV","ticker":"LKFT"},{"name":"Bank of America Corporation","ticker":"BAC","relationship":"shareholder"},{"name":"Bank of America, National Association","relationship":"shareholder affiliate"},{"name":"Merrill Lynch International","relationship":"shareholder affiliate"},{"name":"BofA Securities, Inc.","relationship":"shareholder affiliate"},{"name":"Merrill Lynch, Pierce, Fenner & Smith Incorporated","relationship":"shareholder affiliate"},{"name":"U.S. Trust Company of Delaware","relationship":"shareholder affiliate"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-24T20:07:43.542Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"small-mid-cap","eventGravity":"regulatory_disclosure","sectorWeight":"biotech"}},"durationMs":213950,"modelName":"glm-4.7"}}